Amiodarone inhibits arterial thrombus formation and tissue factor translation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 12, 2008, Pages 2231-2238

  Breitenstein, A ^a   Stampfli S F ^a,b   Camici, G G ^a   Akhmedov, A ^a   Ha, H R ^b   Follath, F ^b   Bogdanova, A ^a,b   Luscher T F ^a,b   Tanner, Felix C ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Amiodarone; SCD; Thrombosis; Tissue factor

Indexed keywords

AMIODARONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; C57BL 6 MOUSE; CARDIAC PATIENT; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOGENESIS; TRANSLATION REGULATION;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CAROTID ARTERY INJURIES; CAROTID ARTERY THROMBOSIS; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; THROMBOPLASTIN;

EID: 57549088129     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.171272     Document Type: Article

References (46)

1. Goldstein S. The necessity of a uniform definition of sudden coronary death: witnessed death within 1 hour of the onset of acute symptoms. Am Heart J. 1982;103:156-159.
2. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158-2163.
3. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473-1482.
4. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98:2334-2351.
5. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med. 1993;119:1187-1197.
6. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 1995;92:1701-1709.
7. Davies MJ, Bland JM, Hangartner JR, Angelini A, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J. 1989;10:203-208.
8. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310:1137-1140.
9. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005;105:192-198.
10. Steffel J, Hermann M, Greutert H, Gay S, Luscher TF, Ruschitzka F, Tanner FC. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation. 2005;111:1685-1689.
11. Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood. 1997;89:541-549.
12. Steffel J, Akhmedov A, Greutert H, Luscher TF, Tanner FC. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation. 2005;112:341-349.
13. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997;349:769-771.
14. Dolack GL. Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE trial). Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation. Am J Cardiol. 1994;73:237-241.
15. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990;16:1711-1718.
16. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol. 1999;84:11R-19R.
17. Charlier R, Deltour G, Tondeur R, Binon F. [Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta- N-diethylaminoethoxybenzoyl)-benzofuran.]. Arch Int Pharmacodyn Ther. 1962;139:255-264.
18. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J. 1983;106:788-797.
19. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970;39:657-667.
20. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet. 1997;350:1417-1424.
21. Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, Shojaati K, Matter CM, Yang Z, Luscher TF, Tanner FC. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation. 2006;114:1512-1521.
22. Steffel J, Iseli S, Arnet C, Luscher TF, Tanner FC. Cocaine unbalances endothelial tissue factor and tissue factor pathway inhibitor expression. J Mol Cell Cardiol. 2006;40:746-749.
23. Ha HR, Bigler L, Wendt B, Maggiorini M, Follath F. Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients. Eur J Pharm Sci. 2005;24:271-279.
24. Lubin M, Ennis HL. On the role of intracellular potassium in protein synthesis. Biochim Biophys Acta. 1964;80:614-631.
25. Stahli BE, Breitenstein A, Akhmedov A, Camici GG, Shojaati K, Bogdanov N, Steffel J, Ringli D, Luscher TF, Tanner FC. Cardiac glycosides regulate endothelial tissue factor expression in culture. Arterioscler Thromb Vasc Biol. 2007;27:2769-2776.
26. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J. 1983;106:840-847.
27. Candinas R, Frielingsdorf J, Ha HR, Carrel T, Turina M, Follath F. Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. Eur J Clin Pharmacol. 1998;53:331-336.
28. Gonzalez ER, Kannewurf BS, Ornato JP. Intravenous amiodarone for ventricular arrhythmias: overview and clinical use. Resuscitation. 1998;39:33-42.
29. Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol. 1987;65:360-364.
30. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13-29.
31. Nattel S. Pharmacodynamic studies of amiodarone and its active N-desethyl metabolite. J Cardiovasc Pharmacol. 1986;8:771-777.
32. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1-8.
33. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006;36:104-107.
34. McBane RD II, Miller RS, Hassinger NL, Chesebro JH, Nemerson Y, Owen WG. Tissue prothrombin. Universal distribution in smooth muscle. Arterioscler Thromb Vasc Biol. 1997;17:2430-2436.
35. Pedersen B, Holscher T, Sato Y, Pawlinski R, Mackman N. A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood. 2005;105:2777-2782.
36. Hudig F, Bakker O, Wiersinga WM. Amiodarone decreases gene expression of low-density lipoprotein receptor at both the mRNA and the protein level. Metabolism. 1998;47:1052-1057.
37. Shi RQ, Lee JK, Hayashi Y, Takeuchi Y, Kambe F, Futaki S, Seo H, Murata Y, Kodama I. Long-term amiodarone treatment causes cardioselective hypothyroid-like alteration in gene expression profile. Eur J Pharmacol. 2008;578:270-278.
38. Vassy R, Starzec A, Yin Y, Nicolas P, Perret GY. Amiodarone has exclusively non-genomic action on cardiac beta-adrenoceptor regulation. Eur J Pharmacol. 2000;408:227-232.
39. Le Bouter S, El Harchi A, Marionneau C, Bellocq C, Chambellan A, van Veen T, Boixel C, Gavillet B, Abriel H, Le Quang K, Chevalier JC, Lande G, Leger JJ, Charpentier F, Escande D, Demolombe S. Long-term amiodarone administration remodels expression of ion channel transcripts in the mouse heart. Circulation. 2004;110:3028-3035.
40. Ha HR, Stieger B, Grassi G, Altorfer HR, Follath F. Structure-effect relationships of amiodarone analogues on the inhibition of thyroxine deiodination. Eur J Clin Pharmacol. 2000;55:807-814.
41. Bolt MW, Card JW, Racz WJ, Brien JF, Massey TE. Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. J Pharmacol Exp Ther. 2001;298:1280-1289.
42. Daniels JM, Brien JF, Massey TE. Pulmonary fibrosis induced in the hamster by amiodarone and desethylamiodarone. Toxicol Appl Pharmacol. 1989;100:350-359.
43. Quaglino D, Ha HR, Duner E, Bruttomesso D, Bigler L, Follath F, Realdi G, Pettenazzo A, Baritussio A. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. Am J Physiol Lung Cell Mol Physiol. 2004;287:L438-L447.
44. Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 2000;67:642-652.
45. Amico JA, Richardson V, Alpert B, Klein I. Clinical and chemical assessment of thyroid function during therapy with amiodarone. Arch Intern Med. 1984;144:487-490.
46. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. 1997;126:63-73.